Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

Next Previous
Trial Profile

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mevrometostat (Primary) ; Enzalutamide
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Mevpro-2
  • Sponsors Pfizer

Most Recent Events

  • 09 Jan 2026 Planned primary completion date changed from 24 Jul 2026 to 2 Dec 2026.
  • 01 Nov 2024 Planned initiation date changed from 1 Oct 2024 to 22 Oct 2024.
  • 17 Oct 2024 Planned initiation date changed from 24 Sep 2024 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top